Crispr Therapeutics Ag Stock Today
| CRSP Stock | USD 56.16 0.60 1.08% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Crispr Therapeutics is selling at 56.16 as of the 19th of April 2024; that is 1.08 percent increase since the beginning of the trading day. The stock's last reported lowest price was 55.25. Crispr Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Crispr Therapeutics AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of October 2016 | Category Healthcare | Classification Health Care |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. The company has 84.88 M outstanding shares of which 14.76 M shares are currently shorted by private and institutional investors with about 10.24 trading days to cover. More on Crispr Therapeutics AG
Moving together with Crispr Stock
| 0.74 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Moving against Crispr Stock
| 0.68 | MRKR | Marker Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 13th of May 2024
Crispr Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Crispr Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Crispr Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Co-Founder, Director | Rodger Novak | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Crispr Therapeutics report their recommendations after researching Crispr Therapeutics' financial statements, talking to executives and customers, or listening in on Crispr Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Crispr Therapeutics. The Crispr consensus assessment is calculated by taking the average forecast from all of the analysts covering Crispr Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Crispr Therapeutics' liquidity, profitability, solvency, and operating efficiency, Crispr Therapeutics AG is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Crispr Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Crispr Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Crispr Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Crispr Therapeutics' financial leverage. It provides some insight into what part of Crispr Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Crispr Therapeutics AG (CRSP) is traded on NASDAQ Exchange in USA. It is located in Baarerstrasse 14, Zug, Switzerland, 6300 and employs 407 people. Crispr Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.77 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Crispr Therapeutics's market, we take the total number of its shares issued and multiply it by Crispr Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Crispr Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 84.88 M outstanding shares of which 14.76 M shares are currently shorted by private and institutional investors with about 10.24 trading days to cover.
Crispr Therapeutics AG currently holds about 2.07 B in cash with (260.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.48.
Check Crispr Therapeutics Probability Of Bankruptcy
Ownership AllocationCrispr Therapeutics holds a total of 84.88 Million outstanding shares. Over half of Crispr Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Crispr Therapeutics. Please watch out for any change in the institutional holdings of Crispr Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Crispr Ownership Details
Crispr Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Crispr Therapeutics jumping above the current price in 90 days from now is over 95.24%. The Crispr Therapeutics AG probability density function shows the probability of Crispr Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.8018 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Crispr Therapeutics will likely underperform. Additionally, crispr Therapeutics AG has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Crispr Therapeutics to move above the current price in 90 days from now is over 95.24 (This Crispr Therapeutics AG probability density function shows the probability of Crispr Stock to fall within a particular range of prices over 90 days) .
Crispr Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Crispr Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Crispr Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Crispr Therapeutics' value.| Instituion | Recorded On | Shares | |
| Bellevue Group Ag | 2023-12-31 | 900.4 K | |
| Geode Capital Management, Llc | 2023-12-31 | 883.7 K | |
| Credit Suisse First Boston (csfb) | 2023-12-31 | 876.1 K | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 864.3 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 779.5 K | |
| Bank Of America Corp | 2023-12-31 | 691.2 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 653 K | |
| Norges Bank | 2023-12-31 | 617.6 K | |
| Federated Hermes Inc | 2023-12-31 | 508.1 K | |
| Ark Investment Management Llc | 2023-12-31 | 8.5 M | |
| Capital Research & Mgmt Co - Division 3 | 2023-12-31 | 6.1 M |
Crispr Therapeutics Historical Income Statement
Crispr Therapeutics AG Income Statement is one of the three primary financial statements used for reporting Crispr's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Crispr Therapeutics revenue and expense. Crispr Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Crispr Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 04/19/2024, Interest Expense is likely to grow to about 56.6 M, while Other Operating Expenses is likely to drop slightly above 305.5 M. View More FundamentalsCrispr Stock Against Markets
Picking the right benchmark for Crispr Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Crispr Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Crispr Therapeutics is critical whether you are bullish or bearish towards Crispr Therapeutics AG at a given time. Please also check how Crispr Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Crispr Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Crispr Therapeutics Corporate Directors
Crispr Therapeutics corporate directors refer to members of a Crispr Therapeutics board of directors. The board of directors generally takes responsibility for the Crispr Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Crispr Therapeutics' board members must vote for the resolution. The Crispr Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Simeon George | Independent Director | Profile | |
| Ali Behbahani | Independent Director | Profile | |
| Jim Kasinger | General Counsel, Secretary to the Board of Directors | Profile | |
| Thomas Woiwode | Independent Director | Profile |
How to buy Crispr Stock?
Before investing in Crispr Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Crispr Therapeutics. To buy Crispr Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Crispr Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Crispr Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Crispr Therapeutics AG stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Crispr Therapeutics AG stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Crispr Therapeutics AG, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Crispr Stock please use our How to Invest in Crispr Therapeutics guide.
Already Invested in Crispr Therapeutics AG?
The danger of trading Crispr Therapeutics AG is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Crispr Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Crispr Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Crispr Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Crispr Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Crispr Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Crispr Therapeutics Ag Stock. Highlighted below are key reports to facilitate an investment decision about Crispr Therapeutics Ag Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.94) | Revenue Per Share 4.686 | Quarterly Revenue Growth 33.5 K | Return On Assets (0.06) | Return On Equity (0.08) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.